The Kidney Fibrosis drugs in development market research report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Kidney Fibrosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued products.
GlobalData tracks 60 drugs in development for Kidney Fibrosis by 48 companies/universities/institutes. The top development phase for Kidney Fibrosis is preclinical with 48 drugs in that stage. The Kidney Fibrosis pipeline has 53 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Kidney Fibrosis pipeline products market are: Elicio Therapeutics, Sapiens Bio and Notable Labs.
The key targets in the Kidney Fibrosis pipeline products market include Transforming Growth Factor Beta 1 (TGFB1), Epithelial Discoidin Domain Containing Receptor 1 (CD167 Antigen Like Family Member A or Mammary Carcinoma Kinase 10 or Protein Tyrosine Kinase 3A or Protein Tyrosine Kinase RTK 6 or Tyrosine Protein Kinase CAK or CD167a or DDR1 or EC 2.7.10.1), and Cytosolic Phospholipase A2 (Phospholipase A2 Group IVA or PLA2G4A or EC 3.1.1.4 or EC 3.1.1.5).
The key mechanisms of action in the Kidney Fibrosis pipeline product include Transforming Growth Factor Beta 1 (TGFB1) Inhibitor with four drugs in Preclinical. The Kidney Fibrosis pipeline products include six routes of administration with the top ROA being Oral and nine key molecule types in the Kidney Fibrosis pipeline products market including Small Molecule, and Monoclonal Antibody.
Kidney Fibrosis overview
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors, and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea, and vomiting. The condition may be managed with medication and kidney transplant.
For a complete picture of Kidney Fibrosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
